Duration of Antimuscarinic Administration for Treatment of Overactive Bladder Before Which One Can Assess Efficacy: An Analysis of Predictive Factors
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: To determine the duration of antimuscarinic therapy for overactive bladder syndrome (OAB) appropriate for assessment of the efficacy of treatment, and to evaluate the possible predictive factors for response to therapy. Methods: All OAB patients who visited a urology outpatient clinic of a tertiary referral center and who were prescribed 5 mg of solifenacin or 4 mg of tolterodine extended release capsules daily were enrolled in the study. Patients were asked to continue therapy for 6 months. All enrolled patients completed the patient perception of bladder condition, overactive bladder symptom score (OABSS), and the modified Indevus Urgency Severity Scale questionnaires. All patients underwent uroflowmetry. Results: A total of 164 patients were enrolled and 125 patients (76%) had at least one follow-up visit. The mean follow-up interval was 1 month (range, 0.5–6 months). Sixty-two patients (49.6%; 95% confidence interval [CI], 40.7–58.5) responded to antimuscarinic treatment. The median time for the onset of response was 3 months (95% CI, 1–6). Multivariate Cox proportional- hazards model revealed that elevated baseline OABSS was an independent predictor of responsiveness to therapy. Receiver operating characteristic (ROC) curve analysis revealed an optimal OABSS cutoff value of ≥7, with an area under the ROC curve of 0.79 (95% CI, 0.70–0.88; sensitivity, 91.9%; specificity, 60.7%). Conclusions: The median time for a therapeutic response was 3 months, and OABSS was the only predictor for responsiveness. These findings may serve as a guideline when prescribing antimuscarinic treatment for OAB patients.
Abstract
Purpose: To determine the duration of antimuscarinic therapy for overactive bladder syndrome (OAB) appropriate for assessment of the efficacy of treatment, and to evaluate the possible predictive factors for response to therapy. Methods: All OAB patients who visited a urology outpatient clinic of a tertiary referral center and who were prescribed 5 mg of solifenacin or 4 mg of tolterodine extended release capsules daily were enrolled in the study. Patients were asked to continue therapy for 6 months. All enrolled patients completed the patient perception of bladder condition, overactive bladder symptom score (OABSS), and the modified Indevus Urgency Severity Scale questionnaires. All patients underwent uroflowmetry. Results: A total of 164 patients were enrolled and 125 patients (76%) had at least one follow-up visit. The mean follow-up interval was 1 month (range, 0.5–6 months). Sixty-two patients (49.6%; 95% confidence interval [CI], 40.7–58.5) responded to antimuscarinic treatment. The median time for the onset of response was 3 months (95% CI, 1–6). Multivariate Cox proportional- hazards model revealed that elevated baseline OABSS was an independent predictor of responsiveness to therapy. Receiver operating characteristic (ROC) curve analysis revealed an optimal OABSS cutoff value of ≥7, with an area under the ROC curve of 0.79 (95% CI, 0.70–0.88; sensitivity, 91.9%; specificity, 60.7%). Conclusions: The median time for a therapeutic response was 3 months, and OABSS was the only predictor for responsiveness. These findings may serve as a guideline when prescribing antimuscarinic treatment for OAB patients.
참고문헌 (26)
- Hsiao SM, "Psychometric assessment of female overactive bladder syndrome and antimuscarinics- related effects", Maturitas, 79, pp.428~434 (2014)
- Hsiao SM, "Autonomic dysfunction and arterial stiffness in female overactive bladder patients and antimuscarinics related effects", Maturitas, 79, pp.65~69 (2014)
- Abrams P, "Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome", Int J Urol, 13, pp.692~698 (2006)
- Jacquetin B, "Tolterodine reduces the number of urge incontinence episodes in patients with an overactive bladder", Eur J Obstet Gynecol Reprod Biol, 98, pp.97~102 (2001)
- Altan-Yaycioglu R, "Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial", Br J Clin Pharmacol, 59, pp.588~592 (2005)
- Herschorn S, "Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial", J Urol, 183, pp.1892~1898 (2010)
- Chapple CR, "Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg", Eur Urol, 52, pp.1195~1203 (2007)
- Novara G, "A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder", Eur Urol, 54, pp.740~763 (2008)
- Visco AG, "Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence", N Engl J Med, 367, pp.1803~1813 (2012)
- Halaska M, "Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability", World J Urol, 20, pp.392~399 (2003)
- Yokoyama T, "Long-term safety and efficacy of two different antimuscarinics, imidafenacin and solifenacin, for treatment of overactive bladder: a prospective randomized controlled study", Urol Int, 90, pp.161~167 (2013)
- Versi E, "Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group", Obstet Gynecol, 95, pp.718~721 (2000)
- Nitti VW, "Can we predict which patient will fail drug treatment for overactive bladder? A think tank discussion", Neurourol Urodyn, 29, pp.652~657 (2010)
- Coyne KS, "The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder", Eur Urol, 49, pp.1079~1086 (2006)
- Homma Y, "Symptom assessment tool for overactive bladder syndrome- -overactive bladder symptom score", Urology, 68, pp.318~323 (2006)
- Nixon A, "A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials", J Urol, 174, pp.604~607 (2005)
- Barry MJ, "The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association", J Urol, 148, pp.1549~1557 (1992)
- Chung SD, "Urgency severity scale could predict urodynamic detrusor overactivity in patients with overactive bladder syndrome", Neurourol Urodyn, 30, pp.1300~1304 (2011)
- Gotoh M, "Responsiveness and minimal clinically important change in overactive bladder symptom score", Urology, 78, pp.768~773 (2011)
- Kuo HC, "Effectiveness of intravesical resiniferatoxin for anticholinergic treatment refractory detrusor overactivity due to nonspinal cord lesions", J Urol, 170, pp.835~839 (2003)
- Kuo HC, "Therapeutic effect of multiple resiniferatoxin intravesical instillations in patients with refractory detrusor overactivity: a randomized, double-blind, placebo controlled study", J Urol, 176, pp.641~645 (2006)
- Natalin R, "Triple therapy in refractory detrusor overactivity: a preliminary study", World J Urol, 28, pp.79~85 (2010)
- Brubaker L, "Refractory idiopathic urge urinary incontinence and botulinum A injection", J Urol, 180, pp.217~222 (2008)
- Hsiao SM, "Factors associated with a better therapeutic effect of solifenacin in patients with overactive bladder syndrome", Neurourol Urodyn, 33, pp.331~334 (2014)
- Chung SD, "The efficacy of additive tolterodine extended release for 1-year in older men with storage symptoms and clinical benign proastatic hyperplasia", Neurourol Urodyn, 30, pp.568~571 (2011)
- D’Souza AO, "Persistence, adherence, and switch rates among extended-release and immediate- release overactive bladder medications in a regional managed care plan", J Manag Care Pharm, 14, pp.291~301 (2008)